By David Bautz, PhD
NASDAQ: ONCY
READ THE FULL ONCY RESEARCH REPORT
We are initiating coverage of Oncolytics Biotech (NASDAQ: ONCY) with a valuation of $6.00. Oncolytics is a clinical-stage immuno-oncology company advancing pelareorep, a systemically delivered oncolytic virus that selectively replicates in cancer cells and enhances anti-tumor immune responses. Pelareorep has been evaluated across multiple tumor types and combination regimens and has demonstrated the ability to induce tumor-directed immune activation, including increased T-cell infiltration and upregulation of immune checkpoint pathways, supporting its positioning as a potential immune priming agent in combination with checkpoint inhibitors.
Following a strategic reset under new management in June 2025, the company has narrowed its focus to GI indications, specifically second-line metastatic colorectal cancer (mCRC) and second-line or later unresectable squamous cell anal carcinoma (SCAC). This transition reflects a deliberate shift toward indications with both strong biological rationale and clearly defined regulatory pathways, as well as a capital-efficient development strategy centered on combination therapy with established immuno-oncology agents. In particular, both mCRC and SCAC represent tumor types where checkpoint inhibitors alone have demonstrated limited efficacy, creating an opportunity for therapies capable of enhancing tumor immunogenicity and restoring sensitivity to immunotherapy.
A key element of this strategy is Oncolytics’ engagement with the FDA to pursue a single-arm pivotal study in SCAC, a rare disease setting with high unmet need and no clearly established standard of care in later lines of therapy. This approach is expected to be informed by the regulatory precedent potentially established by Replimune Group, whose oncolytic immunotherapy RP1 is currently under FDA review (PDUFA date: April 10, 2026) based on data from a single-arm study in anti–PD-1–refractory melanoma. A favorable outcome for RP1 would represent a significant validation not only of the oncolytic virus class, but also of a capital-efficient regulatory pathway based on response-driven endpoints in high unmet need populations.
Oncolytics is scheduled to meet with the FDA in mid-April, positioning the company to potentially incorporate regulatory feedback informed by the outcome of the RP1 review into its own development strategy. We view this sequence of events as a critical near-term inflection point, with the potential to meaningfully impact both the design and timeline of Oncolytics’ SCAC program, as well as broader investor perception of the oncolytic virus space.
- Regulatory precedent may unlock an approval pathway in SCAC. A potential approval of RP1 based on single-arm data could establish a clear framework for ONCY to pursue a similar strategy in a rare, high unmet need indication, significantly reducing development timelines and capital requirement.
- Pelareorep is a differentiated immunotherapy backbone with multi-modal activity. The therapy combines selective viral replication, immunogenic cell death, and systemic immune activation, positioning it as a potential sensitizer to checkpoint inhibitors in immunologically “cold” tumors such as MSS colorectal cancer and SCAC.
- Focused development strategy improves probability of success. The company has transitioned from a diffuse pipeline to a targeted approach centered on two indications with strong mechanistic rationale and defined regulatory pathways, enabling more efficient allocation of capital and resources.
- Attractive risk/reward driven by near-term catalysts. The April 2026 FDA meeting, the outcome of the RP1 PDUFA decision, and continued clinical updates from ongoing studies represent key drivers of potential revaluation in the near to intermediate term.
Valuation
We value Oncolytics using probability-adjusted peak sales estimates for each of the three core indications of SCAC, mCRC, and mPDAC, discounted to present value using a 15% rate, and applying a 3.0x multiple to risk-adjusted revenues, which is consistent with comparable clinical-stage oncology assets. For each indication, we model for peak sales to be seven years following approval.
- For SCAC, we model a 2028 BLA filing and a 2029 launch enabled by a potential single-arm registration pathway, with peak U.S. sales of approximately $250 million and peak E.U. sales of approximately $150 million. We estimate a 60% probability of approval for this indication. This leads to an NPV in SCAC of $169 million.
- For mCRC, we model for a 2030 BLA filing and a 2031 launch with peak U.S. sales of approximately $1.1 billion and peak E.U. sales of approximately $700 million. We estimate a 50% probability of approval for this indication. This leads to an NPV in mCRC of $477 million.
- For mPDAC, we model for a 2030 BLA filing and a 2031 launch with peak U.S. sales of approximately $1.2 billion in the U.S. and peak E.U. sales of approximately $800 million. We estimate a 30% probability of approval for this indication. This leads to an NPV in mPDAC of $371 million.
Combining the contributions from each product results in a total NPV of just over $1 billion. Adding in the current cash position ($5 million) and the potential cash from warrant exercises ($42 million) and dividing by the fully diluted share count, plus an additional 20 million shares for dilution, leads to a valuation of $6.00 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.